Skip to main content
. 2012 Feb;10(1):37–45. doi: 10.1089/adt.2011.0392

Fig. 4.

Fig. 4.

The impact of forskolin pretreatment on P2Y agonist-induced DMR. (a) The ATP DMR in the absence (Control) and presence of 5 μM forskolin. (b) The dose-dependent modulation of the ATP DMR by forskolin. Both early and late ATP P-DMR amplitudes were plotted as a function of forskolin. (c) The 2-MeSATP DMR in the absence (Control) and presence of 5 μM forskolin. (d) The dose-dependent modulation of the 2-MeSATP DMR by forskolin. Both early and late 2-MeSATP P-DMR amplitudes were plotted as a function of forskolin. The concentration was 0.4 μM and 3.2 μM for 2-MeSATP and ATP, respectively. Data presented are means±SEM of four replicate wells (n=4).